

### This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
<b>Infectious disease</b>				
Malaria	<i>Plasmodium falciparum</i> MetAP2 (MetAP2)	<i>In vitro</i> and mouse studies suggest that the fumagillin analog fumarranol could help treat malaria. In both chloroquine-sensitive and drug-resistant <i>P. falciparum</i> , the MetAP2 inhibitor fumarranol blocked the parasite's growth. In mice infected with a chloroquine-resistant strain of <i>P. falciparum</i> , fumarranol decreased parasitemia and increased survival compared with that seen using the MetAP2 inhibitor TNP-470 or chloroquine. Next steps include optimizing the potency of fumarranol.	Composition of matter for fumarranol patented; available for licensing in the U.S.	Chen, X. <i>et al. Cell</i> ; published online Feb. 26, 2009; doi:10.1016/j.chembiol.2009.01.006 <b>Contact:</b> Jun O. Liu, The Johns Hopkins University School of Medicine, Baltimore, Md. e-mail: <a href="mailto:joliu@jhu.edu">joliu@jhu.edu</a> <b>Contact:</b> Theresa A. Shapiro, same affiliation as above e-mail: <a href="mailto:tshapiro@jhmi.edu">tshapiro@jhmi.edu</a>
		<b>SciBX 2(9); doi:10.1038/scibx.2009.364</b> Published online March 5, 2009		